David P. Carbone, MD, PhD, describes variations in the accuracy and availability of genetic testing technologies for patients with lung cancer.
David P. Carbone, MD, PhD, a professor in the Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center, describes variations in the accuracy and availability of genetic testing technologies for patients with lung cancer.
Across the country, there is not only uneven access to genetic testing but also variations in accuracy, explains Carbone. Each test for EGFR is not the same, as some exclude rare mutations. As such, there is currently a transition under way in genetic testing.
Despite this transition, immunohistochemistry may be a better approach in some situations, since it can focus more on the protein. The ideal test, Carbone notes, would focus on the protein, since this is generally what is targeted by treatment. However, at this point, protein-specific data and tests are less developed than genetic testing.
Clinical Pearls
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
March 25th 2024During a Case-Based Roundtable® event, Christine, Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non–small cell lung cancer in the first article of a 2-part series.
Read More
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More